Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuroone Medical Technologies (NMTC) Change in Cash (2016 - 2025)

Historic Change in Cash for Neuroone Medical Technologies (NMTC) over the last 14 years, with Q4 2025 value amounting to -$3.0 million.

  • Neuroone Medical Technologies' Change in Cash fell 82380.72% to -$3.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $2.4 million, marking a year-over-year increase of 25693.85%. This contributed to the annual value of $5.1 million for FY2025, which is 23230.82% up from last year.
  • Neuroone Medical Technologies' Change in Cash amounted to -$3.0 million in Q4 2025, which was down 82380.72% from -$1.5 million recorded in Q3 2025.
  • Neuroone Medical Technologies' 5-year Change in Cash high stood at $9.3 million for Q4 2021, and its period low was -$3.5 million during Q4 2022.
  • Moreover, its 5-year median value for Change in Cash was -$939973.5 (2023), whereas its average is -$178374.8.
  • The largest annual percentage gain for Neuroone Medical Technologies' Change in Cash in the last 5 years was 92479.61% (2025), contrasted with its biggest fall of 82380.72% (2025).
  • Over the past 5 years, Neuroone Medical Technologies' Change in Cash (Quarter) stood at $9.3 million in 2021, then tumbled by 137.63% to -$3.5 million in 2022, then grew by 24.37% to -$2.6 million in 2023, then surged by 87.67% to -$325692.0 in 2024, then crashed by 823.81% to -$3.0 million in 2025.
  • Its Change in Cash was -$3.0 million in Q4 2025, compared to -$1.5 million in Q3 2025 and $6.7 million in Q2 2025.